CLINICAL TRIALS PROFILE FOR AFATINIB DIMALEATE
✉ Email this page to a colleague
All Clinical Trials for afatinib dimaleate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02122172 ↗ | Afatinib in Advanced Refractory Urothelial Cancer | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2013-10-30 | This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die. |
NCT02122172 ↗ | Afatinib in Advanced Refractory Urothelial Cancer | Recruiting | University of Chicago | Phase 2 | 2013-10-30 | This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die. |
NCT02131259 ↗ | Long-term Observation PMS for Afatinib | Completed | Boehringer Ingelheim | 2014-05-07 | In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data for reexamination. Reexamination period is defined by J-PAL. Eight years after approval of a new substance, results of PMS need to be submitted as a part of reexamination dossier to the Japanese regulatory authority, the Ministry of Health, Labour and Welfare (MHLW). | |
NCT02285361 ↗ | GIOTRIF rPMS in Korean Patients With NSCLC | Completed | Boehringer Ingelheim | 2014-10-31 | To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for afatinib dimaleate
Condition Name
Condition Name for afatinib dimaleate | |
Intervention | Trials |
Advanced Malignant Solid Neoplasm | 3 |
Refractory Malignant Solid Neoplasm | 2 |
Stage IV Non-Small Cell Lung Cancer | 2 |
Recurrent Pancreatic Carcinoma | 2 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for afatinib dimaleate
Trials by Country
Clinical Trial Progress for afatinib dimaleate
Clinical Trial Phase
Clinical Trial Sponsors for afatinib dimaleate
Sponsor Name